potential COVID-19 treatments living meta-analysis of clinical studies

demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only observational study

	COVID 19 all comers

	COVID 19 all comers
potential COVID-19 treatments
anti-inflammatoty and immuno-therapy
Immunostimulants drugs
convalescent plasma treatment	LIFESAVER
interferon	Cai -FAVIPIRAVIR Cai -FAVIPIRAVIR
neutralizing antibody
cilgavimab and tixagevimab (Evusheld)	Chen
Immunosuppressants drugs
anti-interleukin-6
sarilumab
sarilumab high dose (400mg)	sarilumab phase 2 high dose
sarilumab low dose (200mg)	sarimulab phase 2 low dose
tocilizumab	BACC Bay Tocilizumab Trial TOCOVID
janus kinase (JAK) inhibitor
baricitinib	RECOVERY
leflunomide	Wang
antiviral and associated therapy
chloroquine and derivatives
chloroquine	Chen, ChiCTR2000030054 - Chloroquine
hydroxychloroquine	NCT04376814-Group A NOR-Solidarity ... NCT04376814-Group A Gautret et al. IRCT20150808023559N20 ChiCTR2000030054-HCQ ... IRCT20150808023559N20
darunavir cobicistat	Jun C
favipiravir	Chang Chen et al. NCT04376814-Group A Cai -FAVIPIRAVIR NCT04310228-FAVI ... NCT04376814-Group A Lou ... IRCT20150808023559N20 Calik jRCTs041190120 IRCT20150808023559N20 Cai -FAVIPIRAVIR
hydroxychloroquine plus macrolides	Magagnoli ...
nirmatrelvir / ritonavir (Paxlovid)	EPIC-SR
remdesivir	Norwegian NOR study ... Andreas ...
umifenovir (arbidol)	ELACOI ...
miscellaneous
aviptadil	COVID-AIV
camostat mesilate	Gunst JD
Oral antidiabetic drugs
DPP-4 inhibitor	Rhee ... Rhee ... Noh
Renin-angiotensin-system-acting agents	Yang Bean Zhang Li Meng Yan et al.
angiotensin receptor blockers (ARBs)
losartan	University of Minnesota